OncoMatch/Clinical Trials/NCT06291064
Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
Is NCT06291064 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for triple negative breast cancer.
Treatment: Cyclophosphamide · Epirubicin · Docetaxel · Carboplatin · Capecitabine — The primary purpose of this study is to determine what proportion of participants will achieve complete pathological response with epirubicin+ cyclophosphamide followed by docetaxel +carboplatin. This will also examine the potential of using signals in the blood (biomarkers) to identify resistance to chemotherapy in Nigerian women with triple negative breast cancer (TNBC). All enrollment to this trial will occur at sites in Nigeria. University of Chicago is serving as coordinating center and will be involved in data analysis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: ESR1 low estrogen receptor expression (< 20%) (< 20%)
low estrogen reception (ER) expression (< 20%)
Required: PR (PGR) negative (negative)
progesterone receptor (PR) negative
Required: HER2 (ERBB2) negative (negative)
human epidermal growth factor 2 (HER2) negative
Disease stage
Required: Stage IIA, IIB, IIIA, IIIB, IIIC (AJCC 2009)
Clinical stages IIA -IIIC (AJCC 2009)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Blood counts
Granulocyte ≥ 1,500/microliter; Platelet count ≥ 100,000/microliter; ANC ≥ 1,500/microliter; Hemoglobin ≥ 10g/dL
Kidney function
Creatinine within institutional normal limits or GFR ≥ 30 mL/min/1.73 m2 by CKD EPI equation
Liver function
Bilirubin ≤ 1.5 x ULN; AST/ALT < 2.5 x ULN
Cardiac function
Baseline left ventricular ejection fraction ≥ 55%
Granulocyte ≥ 1,500/microliter; Platelet count ≥ 100,000/microliter; ANC ≥ 1,500/microliter; Hemoglobin ≥ 10g/dL; Bilirubin ≤ 1.5 x ULN; AST/ALT < 2.5 x ULN; Creatinine within institutional normal limits or GFR ≥ 30 mL/min/1.73 m2 by CKD EPI equation; Baseline left ventricular ejection fraction ≥ 55%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06291064 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ESR1?
Yes, ESR1 low estrogen receptor expression (< 20%) is a required biomarker for enrollment.
Does this trial require PGR?
Yes, PGR negative is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 negative is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIA or IIB or IIIA or IIIB or IIIC is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify